Racetams

Results: 39



#Item
21Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl

Add to Reading List

Source URL: www.pmda.go.jp

Language: English - Date: 2015-01-09 03:35:29
22Published by Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency

Published by Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency

Add to Reading List

Source URL: www.pmda.go.jp

Language: English - Date: 2015-01-09 03:35:27
23Levetiracetam Wockhardt 100mg/ml concentrate for solution for infusion  UK/H[removed]DC Public Assessment Report

Levetiracetam Wockhardt 100mg/ml concentrate for solution for infusion UK/H[removed]DC Public Assessment Report

Add to Reading List

Source URL: www.mhra.gov.uk

Language: English - Date: 2015-01-08 11:26:18
24Keppra IV NDA[removed]S-016 FDA Approved Labeling Text October 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEPPRA injection safely and effectively. See f

Keppra IV NDA[removed]S-016 FDA Approved Labeling Text October 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEPPRA injection safely and effectively. See f

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-11-04 13:36:51
25KEPPRA XR NDA[removed]S-020 FDA Approved Labeling Text Aug 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEPPRA XR® safely and effectively. See full prescrib

KEPPRA XR NDA[removed]S-020 FDA Approved Labeling Text Aug 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEPPRA XR® safely and effectively. See full prescrib

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-08-12 12:33:32
26Structural analysis of the positive AMPA receptor modulators CX516 and Me-CX516 in complex with the GluA2 ligand-binding domain

Structural analysis of the positive AMPA receptor modulators CX516 and Me-CX516 in complex with the GluA2 ligand-binding domain

Add to Reading List

Source URL: biomed.health.umt.edu

Language: English - Date: 2013-11-07 17:53:20
27KEPPRA® (levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg tablets 100 mg/mL oral solution Rx only

KEPPRA® (levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg tablets 100 mg/mL oral solution Rx only

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-05-13 08:08:26
2853475_special_request.1_2.pdf

53475_special_request.1_2.pdf

Add to Reading List

Source URL: www.ashp.org

Language: English
29JOINT CLINICAL AND STATISTICAL REVIEW  Application Type SNDA Submission Number[removed]Submission Code S 073 Letter Date March 18, 2008

JOINT CLINICAL AND STATISTICAL REVIEW Application Type SNDA Submission Number[removed]Submission Code S 073 Letter Date March 18, 2008

Add to Reading List

Source URL: www.fda.gov

Language: English
30SAFETY REVIEW: sNDA FOR LEVETIRACETAM USE IN   PEDIATRIC PATIENTS WITH REFACTORY PARTIAL ONSET SEIZURES

SAFETY REVIEW: sNDA FOR LEVETIRACETAM USE IN PEDIATRIC PATIENTS WITH REFACTORY PARTIAL ONSET SEIZURES

Add to Reading List

Source URL: www.fda.gov

Language: English